| Jashia T Pinkney, CNM | |
|
2150 Pennsylvania Ave Nw Fl 5, Washington, DC 20037-3201 | |
| (202) 741-2500 | |
| Not Available |
| Full Name | Jashia T Pinkney |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 6 Years |
| Location | 2150 Pennsylvania Ave Nw Fl 5, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326507302 | NPI | - | NPPES |
| CNM05458 | Other | DC | AMERICAN MIDWIFERY CERTIFICATION BOARD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | CNM05458 (District Of Columbia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medstar Medical Group Ii Llc | 0547413825 | 1776 |
News Archive
An editorial published by The BMJ today raises important concerns about the health and wellbeing of the NHS workforce after a parliamentary report found "burnout is a widespread reality in today's NHS."
A Johns Hopkins-led study of outcomes among 1,200 people with implanted defibrillators - devices intended to prevent sudden cardiac death from abnormal heart rhythms - shows that within a few years of implantation, one in four experienced improvements in heart function substantial enough to put them over the clinical threshold that qualified them to get a defibrillator in the first place.
The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
› Verified 9 days ago
| Entity Name | Medical Faculty Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417990581 PECOS PAC ID: 4082528898 Enrollment ID: O20031117000341 |
News Archive
An editorial published by The BMJ today raises important concerns about the health and wellbeing of the NHS workforce after a parliamentary report found "burnout is a widespread reality in today's NHS."
A Johns Hopkins-led study of outcomes among 1,200 people with implanted defibrillators - devices intended to prevent sudden cardiac death from abnormal heart rhythms - shows that within a few years of implantation, one in four experienced improvements in heart function substantial enough to put them over the clinical threshold that qualified them to get a defibrillator in the first place.
The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
› Verified 9 days ago
| Entity Name | Washington Hospital Center Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407870124 PECOS PAC ID: 3577476266 Enrollment ID: O20040630000173 |
News Archive
An editorial published by The BMJ today raises important concerns about the health and wellbeing of the NHS workforce after a parliamentary report found "burnout is a widespread reality in today's NHS."
A Johns Hopkins-led study of outcomes among 1,200 people with implanted defibrillators - devices intended to prevent sudden cardiac death from abnormal heart rhythms - shows that within a few years of implantation, one in four experienced improvements in heart function substantial enough to put them over the clinical threshold that qualified them to get a defibrillator in the first place.
The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
› Verified 9 days ago
| Entity Name | Medstar Medical Group Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184046187 PECOS PAC ID: 0547413825 Enrollment ID: O20130117000415 |
News Archive
An editorial published by The BMJ today raises important concerns about the health and wellbeing of the NHS workforce after a parliamentary report found "burnout is a widespread reality in today's NHS."
A Johns Hopkins-led study of outcomes among 1,200 people with implanted defibrillators - devices intended to prevent sudden cardiac death from abnormal heart rhythms - shows that within a few years of implantation, one in four experienced improvements in heart function substantial enough to put them over the clinical threshold that qualified them to get a defibrillator in the first place.
The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jashia T Pinkney, CNM 5619 Fish Hawk Ct, Waldorf, MD 20601-4547 Ph: (240) 210-3773 | Jashia T Pinkney, CNM 2150 Pennsylvania Ave Nw Fl 5, Washington, DC 20037-3201 Ph: (202) 741-2500 |
News Archive
An editorial published by The BMJ today raises important concerns about the health and wellbeing of the NHS workforce after a parliamentary report found "burnout is a widespread reality in today's NHS."
A Johns Hopkins-led study of outcomes among 1,200 people with implanted defibrillators - devices intended to prevent sudden cardiac death from abnormal heart rhythms - shows that within a few years of implantation, one in four experienced improvements in heart function substantial enough to put them over the clinical threshold that qualified them to get a defibrillator in the first place.
The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
› Verified 9 days ago
Amanda Booth, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 2150 Pennsylvania Ave Nw, Washington, DC 20037 Phone: 202-741-3000 | |
Brenda Baffour-addo, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7000 | |
Mary Curtis, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 2333 Ontario Rd Nw, Washington, DC 20009 Phone: 202-483-8196 Fax: 202-332-0541 | |
Mindy Greenside, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 2333 Ontario Rd Nw, Washington, DC 20009 Phone: 202-420-7141 Fax: 202-332-0541 | |
Mrs. Ana Luisa Nascimento, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3020 14th St Nw, Washington, DC 20009 Phone: 202-745-4300 Fax: 202-232-8910 | |
Mrs. Karen J Pelote, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 801 17th St Ne, Washington, DC 20002 Phone: 202-398-5529 Fax: 202-396-6953 | |
Ms. Elizabeth Lamme, Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 3828 Georgia Ave Nw, Apt 535, Washington, DC 20011 Phone: 585-727-9042 |